Matches in SemOpenAlex for { <https://semopenalex.org/work/W2091360147> ?p ?o ?g. }
Showing items 1 to 75 of
75
with 100 items per page.
- W2091360147 endingPage "26" @default.
- W2091360147 startingPage "23" @default.
- W2091360147 abstract "In long-term clinical studies the beneficial effects of gliclazide on platelets have been related to a reduction in oxidative stress. This property is because of gliclazide's free radical scavenging ability that relates to the unique amino azabicyclo-octare ring, which is grafted on to the sulfonylurea. During a blinded clinical trial, the possible effects of gliclazide were assessed in 30 non-insulin-dependent diabetic patients. All patients had been treated for diabetes for more than 2 years (mean 8 years) and had been established on glibenclamide for over 2 years with or without adjunctive metformin therapy. Patients were studied for 6 months and randomized to continue either their present dose of glibenclamide or to be converted to an equipotent dose of gliclazide. Measurements were taken of hemostatic variables, the oxidative status of the plasma, and the redox status, both extracellularly as plasma albumin-thiols (PSH) and lipid peroxides, and intracellularly as red blood cell superoxide dismutase activity (SOD). At 3 months, diabetic control was unaltered, but there were significant improvements in the oxidative status of the gliclazide-treated patients. Lipid peroxides decreased (8.3 +/- 1.1 to 7.0 +/- .06 micromol/L, P < .01) and red blood cell SOD increased (135 +/- 21 to 152 +/- 36 microg/mL, P < .05). PSH levels were unaltered at 458 +/- 38 micromol/L, whereas they had decreased significantly in the glibenclamide patients (414 +/- 34 micromol/L, P < .05), resulting in a significant difference between the 2 treatment groups (P < .004). Platelet reactivity to collagen also improved in the gliclazide-treated patients, decreasing from 65.1% +/- 14% to 50.8% +/- 24% (P < .01). The reactivity of the platelets remained unaltered in the glibenclamide patients. At 6 months, the significant differences between the 2 treatment groups remained. Hence, gliclazide was shown in a clinical study to have free radical scavenging activity independent of glycemic control." @default.
- W2091360147 created "2016-06-24" @default.
- W2091360147 creator A5028987042 @default.
- W2091360147 creator A5046482415 @default.
- W2091360147 date "2000-02-01" @default.
- W2091360147 modified "2023-10-01" @default.
- W2091360147 title "Free radical scavenging activity of sulfonylureas: A clinical assessment of the effect of gliclazide" @default.
- W2091360147 cites W2036795397 @default.
- W2091360147 cites W2044845204 @default.
- W2091360147 cites W2074712105 @default.
- W2091360147 cites W2084581086 @default.
- W2091360147 cites W2084784103 @default.
- W2091360147 cites W2097177556 @default.
- W2091360147 doi "https://doi.org/10.1016/s0026-0495(00)80081-5" @default.
- W2091360147 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10693916" @default.
- W2091360147 hasPublicationYear "2000" @default.
- W2091360147 type Work @default.
- W2091360147 sameAs 2091360147 @default.
- W2091360147 citedByCount "54" @default.
- W2091360147 countsByYear W20913601472012 @default.
- W2091360147 countsByYear W20913601472013 @default.
- W2091360147 countsByYear W20913601472015 @default.
- W2091360147 countsByYear W20913601472016 @default.
- W2091360147 countsByYear W20913601472018 @default.
- W2091360147 countsByYear W20913601472019 @default.
- W2091360147 countsByYear W20913601472020 @default.
- W2091360147 countsByYear W20913601472021 @default.
- W2091360147 countsByYear W20913601472022 @default.
- W2091360147 crossrefType "journal-article" @default.
- W2091360147 hasAuthorship W2091360147A5028987042 @default.
- W2091360147 hasAuthorship W2091360147A5046482415 @default.
- W2091360147 hasConcept C126322002 @default.
- W2091360147 hasConcept C134018914 @default.
- W2091360147 hasConcept C185592680 @default.
- W2091360147 hasConcept C2776125364 @default.
- W2091360147 hasConcept C2776151105 @default.
- W2091360147 hasConcept C2777448766 @default.
- W2091360147 hasConcept C2779768347 @default.
- W2091360147 hasConcept C2780323712 @default.
- W2091360147 hasConcept C555293320 @default.
- W2091360147 hasConcept C71924100 @default.
- W2091360147 hasConcept C98274493 @default.
- W2091360147 hasConceptScore W2091360147C126322002 @default.
- W2091360147 hasConceptScore W2091360147C134018914 @default.
- W2091360147 hasConceptScore W2091360147C185592680 @default.
- W2091360147 hasConceptScore W2091360147C2776125364 @default.
- W2091360147 hasConceptScore W2091360147C2776151105 @default.
- W2091360147 hasConceptScore W2091360147C2777448766 @default.
- W2091360147 hasConceptScore W2091360147C2779768347 @default.
- W2091360147 hasConceptScore W2091360147C2780323712 @default.
- W2091360147 hasConceptScore W2091360147C555293320 @default.
- W2091360147 hasConceptScore W2091360147C71924100 @default.
- W2091360147 hasConceptScore W2091360147C98274493 @default.
- W2091360147 hasIssue "2" @default.
- W2091360147 hasLocation W20913601471 @default.
- W2091360147 hasLocation W20913601472 @default.
- W2091360147 hasOpenAccess W2091360147 @default.
- W2091360147 hasPrimaryLocation W20913601471 @default.
- W2091360147 hasRelatedWork W132968848 @default.
- W2091360147 hasRelatedWork W2005084305 @default.
- W2091360147 hasRelatedWork W2016264464 @default.
- W2091360147 hasRelatedWork W2033313326 @default.
- W2091360147 hasRelatedWork W2033324666 @default.
- W2091360147 hasRelatedWork W2072765033 @default.
- W2091360147 hasRelatedWork W2225525964 @default.
- W2091360147 hasRelatedWork W2744240433 @default.
- W2091360147 hasRelatedWork W2748952813 @default.
- W2091360147 hasRelatedWork W4239141576 @default.
- W2091360147 hasVolume "49" @default.
- W2091360147 isParatext "false" @default.
- W2091360147 isRetracted "false" @default.
- W2091360147 magId "2091360147" @default.
- W2091360147 workType "article" @default.